DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Claims
This action is in reply to the amended claims filed on 8/12/26, wherein:
Claims 1-5, and 7-20 are currently pending and have been examined.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claims 1-5, and 7-20 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more. The claims recite a system and method for coordinating a purchase which is considered a judicial exception because it falls under Certain Methods of Organizing Human Activity such as commercial or legal interactions, including sales activities or behaviors. This judicial exception is not integrated into a practical application as discussed below and the claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception as discussed below.
This rejection follows the 2019 Revised Patent Subject Matter Eligibility Guidance, 84 Fed Reg 4, January 7, 2019, pp. 50-57 (“2019 PEG”)(MPEP 2106).
Analysis
Step 1 (Statutory Categories) – 2019 PEG pg. 53 (See MPEP 2106.03)
Claims 1-5, and 7-20 are directed to the statutory category of a process, machine, or manufacture.
Step 2A, Prong 1 (Do the claims recite an abstract idea?) – 2019 PEG pg. 54 (See MPEP 2106.04(a)-(c))
For independent claims 1 and 18, the claims recite an abstract idea of: coordinating a purchase. The steps of independent claim 1 recite the abstract idea (in bold below) of: A computer-based method for coordinating a purchase, the method comprising: receiving, at an exchange platform, an indication that a buyer wishes to purchase a prescription-based product from a primary seller, the primary seller comprising a primary pharmacy at which the buyer seeks to fill the indication; evaluating a hypothetical sale of the prescription-based product from the primary seller, the evaluation being based at least partially on confidential data retrieved from or associated with the primary seller, wherein the confidential data is unique to the primary seller; upon determining that the hypothetical sale of the prescription-based product from the primary seller would not be profitable, evaluating an equivalent hypothetical sale from at least one secondary seller, the secondary seller comprising a dispensing pharmacy separate from the primary pharmacy, the equivalent hypothetical sale being evaluated based at least partially on confidential data retrieved from or associated with the secondary seller; wherein the confidential data of the primary seller is not accessible by the at least one secondary seller and the confidential data of the at least one secondary seller is not accessible by the primary seller; and upon determining that the equivalent hypothetical sale from a selected seller of the at least one secondary seller would be profitable, initiating a transfer of the indication from the primary seller to the selected seller. Independent claim 18 recites similar steps that recite the abstract idea. Independent claims 1 and 18, as drafted, are a process that, under the broadest reasonable interpretation, covers Certain Methods of Organizing Human Activity, since they recite commercial or legal interactions, including sales activities or behaviors. If the claim limitations, under the broadest reasonable interpretation, covers methods of organizing human activity but for the recitation of additional elements including generic computer components, then it falls within the “Certain Methods of Organizing Human Activity” grouping of abstract ideas. Other than reciting the abstract idea, the independent claims recite additional elements including generic computer components such as “an exchange platform; a system comprising a server, a primary seller interface device, and a secondary seller interface device”, and nothing in the claims precludes the steps from being performed as a method of organizing human activity. Accordingly, the independent claims recite an abstract idea.
Dependent claims 2-5, 7-17, 19, and 20 recite similar limitations as independent claims 1 and 18; and when analyzed as a whole are held to be patent ineligible under 35 U.S.C 101 because the additional recited limitations only refine the abstract idea further. Other than reciting the abstract idea, the dependent claims recite similar additional elements including generic computer components as the independent claims, such as “the exchange platform, communication pathways, the server, the primary seller interface device, the secondary seller interface device, and a database”. If a claim limitation, under its broadest reasonable interpretation, covers commercial or legal interactions, but for the recitation of generic computer components, then it falls within the “Certain Methods of Organizing Human Activity” grouping of abstract ideas.
Step 2A, Prong 2 (Does the claim recite additional elements that integrate the judicial exception into a practical application?) – 2019 PEG pg. 54 (See MPEP 2106.04(d)-(c))
This judicial exception is not integrated into a practical application. In particular, independent claims 1 and 18 only recite the additional elements of “an exchange platform; a system comprising a server, a primary seller interface device, and a secondary seller interface device”. A plain reading of the Figures and associated descriptions in the specification reveals that generic processors may be used to execute the claimed steps. The additional elements are recited at a high level of generality (i.e., as a generic processor performing generic computer functions) such that it amounts to no more than mere instructions to apply the exception using generic computer components (See MPEP 2106.05(f)) and limits the judicial exception to a particular environment (See MPEP 2106.05(h)). Mere instructions to apply an exception using a generic computer component and limiting the judicial exception to a particular environment doesn’t integrate the abstract idea into a practical application in Step 2A. Accordingly, these additional elements do not integrate the abstract idea into a practical application because it does not impose any meaningful limits on practicing the abstract idea. Hence, independent claims 1 and 18 are directed to an abstract idea.
Dependent claims 2-5, 7-17, 19, and 20, recite similar additional elements as the independent claims including generic computer components, such as “the exchange platform, communication pathways, the server, the primary seller interface device, the secondary seller interface device, and a database”. The judicial exception is not integrated into a practical application because the additional elements in the dependent claims are also recited at a high-level of generality such that it amounts to more no more than mere instructions to apply the exception using generic computer components. Therefore, the additional elements do not integrate the abstract idea into a practical application because they also do not impose any meaningful limits on practicing the abstract idea. Also, the claims do not affect an improvement to another technology or technical field; the claims do not amount to an improvement of the functioning of a computer system itself; the claims do not effect a transformation or reduction of a particular article to a different state or thing; and the claims do not move beyond a general link of the use of an abstract idea to a particular technological environment.
Step 2B (Does the claim recite additional elements that amount to significantly more than the judicial exception?) – 2019 PEG pg. 56 (See MPEP 2106.05)
Independent claims 1 and 18 do not include additional elements that are sufficient to amount to significantly more than the judicial exception. As discussed above with respect to integration of the abstract idea into a practical application, the recited additional elements amount to no more than mere instructions to apply the exception using a generic computer component (See MPEP 2106.05(f)) and limits the judicial exception to the particular environment of computers (See MPEP 2106.05(h)). The additional elements of the instant underlying process, when taken in combination, together do not offer substantially more than the sum of the function of the elements when each is taken alone. Mere instructions to apply an exception using a generic computer component cannot provide an inventive concept in Step 2B.
In addition, the dependent claims 2-5, 7-17, 19, and 20 do not include additional elements that are sufficient to amount to significantly more than the judicial exception. As discussed above with respect to integration of the abstract idea into a practical application, the additional elements of the dependent claims to perform the claimed limitations, amounts to no more than mere instructions to apply the exception using a generic computer component (See MPEP 2106.05(f)). Similar to the independent claims, mere instructions to apply an exception using a generic computer component cannot provide an inventive concept. Also, for the same reasoning as the independent claims, the additional elements of the limitations of the dependent claims, when considered individually and as an ordered combination, together do not offer significantly more than the sum of the functions of the elements when each is taken alone and the dependent claims as a whole, do not amount to significantly more than the abstract idea itself. For these reasons, the dependent claims also are not patent eligible.
Subject Matter Overcoming 35 USC §102/§103
Claims 1-5, and 7-20 would be allowable if rewritten to overcome the rejections under 35 U.S.C. 101 set forth in this Office Action.
The following is an examiner’s statement of reasons for subject matter of independent claims 1 and 18 overcoming the prior art rejections under 35 USC §102/§103.
The closest prior art of record is US 2023/0049733 to Crane et al. (hereinafter referred to as Crane), US 2021/0210185 to Aldred et al. (hereinafter referred to as Aldred), US 2019/0341139 to Kello et al. (hereinafter referred to as Kello), and US 11,170,394 to Macinski (hereinafter referred to as Macinski). Allowable subject matter is indicated because none of the prior art of record, alone or in combination, appears to teach or fairly suggest or render obvious the combination set forth in independent claims 1 and 18. For independent claim 1, the prior art of Powell, Richey, and Litle specifically do not disclose: “evaluating a hypothetical sale of the prescription-based product from the primary seller, the evaluation being based at least partially on confidential data retrieved from or associated with the primary seller, wherein the confidential data is unique to the primary seller; upon determining that the hypothetical sale of the prescription-based product from the primary seller would not be profitable, evaluating an equivalent hypothetical sale from at least one secondary seller, the secondary seller comprising a dispensing pharmacy separate from the primary pharmacy, the equivalent hypothetical sale being evaluated based at least partially on confidential data retrieved from or associated with the secondary seller; wherein the confidential data of the primary seller is not accessible by the at least one secondary seller and the confidential data of the at least one secondary seller is not accessible by the primary seller; and upon determining that the equivalent hypothetical sale from a selected seller of the at least one secondary seller would be profitable, initiating a transfer of the indication from the primary seller to the selected seller”. Similar reasoning and rationale apply to the other independent claim 18. Dependent claims 2-5, 7-17, 19, and 20 are allowable over the prior art by virtue of their dependency on an allowed claim.
Response to Arguments
Applicant’s arguments with respect to the rejection of claims 1-5, and 7-20 under 35 USC 101 have been fully considered by the Examiner. However, the Examiner does not find the Applicant’s arguments persuasive, and therefore the rejections of claims 1-5, and 7-20 under 35 USC 101 are maintained.
The Applicant argues that under Prong 1 of Step 2A, the claims do not recite an abstract idea directed to Certain Methods of Organizing Human activity such as commercial or legal interactions. The Applicant further states on pages 6-8 of their remarks, that the limitations of the amended independent claims provide a combination of steps that allows for implementation of technical features and tangible results not previously possible that resolves inherent bottlenecks in the pharmacy sales distribution process by performing evaluations of hypothetical primary and secondary pharmacy sales to determine profitability and determine whether a sale should be executed or transferred to a third party. Applicant argues that the evaluation of hypothetical sales do not recite sales activities or behaviors. Applicant further argues on pages 8 and 9 that the amended claims under Prong 2 of Step 2A are indicative of integration into a practical application because they allow for the transfer of a prescription between competing pharmacies which use different underlying confidential data to evaluate a potential sale which a person would not be in a position to determine.
Examiner respectfully disagrees with Applicant’s argument that the claimed limitations do not recite any of the groupings of abstract ideas. Under Prong 1, the claims do fall under the abstract idea of Certain Method of Organizing Human Activity. If a claim limitation, under its broadest reasonable interpretation, covers commercial or legal interactions, including sales activities or behaviors, but for the recitation of additional elements including generic computer components, then it falls within the “Certain Methods of Organizing Human Activity” grouping of abstract ideas. Under the broadest reasonable interpretation, the claims recite sales activities or behaviors. Analyzing a potential sale to determine if it is profitable is a sales activity.
Examiner respectfully disagrees with Applicant’s argument that the claimed limitations are indicative of integration into a practical application under Prong 2 of Step 2A. Using a computer to: receive data and evaluate a hypothetical sale of a prescription by a primary and secondary seller; is nothing more than executing instructions to apply the exception to a computer. This is interpreted by the Examiner as using a computer as a tool to perform an abstract idea (See MPEP 2106.05(f)). The additional elements of “an exchange platform; a system comprising a server, a primary seller interface device, and a secondary seller interface device” are recited at a high level of generality such that it amounts to no more than mere instructions to apply the exception using generic computer components (See MPEP 2106.05(f)). There is no improvement to the claimed computer elements, or to any other technology or technical field. The only improvements identified in the specification are generic speed and efficiency improvements inherent in applying the use of a computer to any task. Therefore, the claimed limitations do not meet the criteria or considerations as indicative of integration into a practical application. Therefore, the rejections of the claims pursuant to 35 USC 101 are maintained.
With respect to the Applicant’s arguments regarding the previous rejection of independent claims under 35 USC 103, the Applicant argues that the prior art fails to disclose the limitations of the amended claims. Examiner finds Applicant’s persuasive the prior art rejections are withdrawn as further detailed in the above final rejection.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Paul Schwarzenberg whose telephone number is (313) 446-6611. The examiner can normally be reached on Monday-Thursday (7:30-6:30).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christine Behncke, can be reached on (571) 272-8103. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PAUL S SCHWARZENBERG/Primary Examiner, Art Unit 3695 10/13/2026